Back to Search
Start Over
Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events.
- Source :
-
Journal of the American Heart Association [J Am Heart Assoc] 2021 May 04; Vol. 10 (9), pp. e018932. Date of Electronic Publication: 2021 Apr 23. - Publication Year :
- 2021
-
Abstract
- Background Familial hypercholesterolemia (FH) may arise from deleterious monogenic variants in FH-causing genes as well as from a polygenic cause. We evaluated the relationships between monogenic FH and polygenic hypercholesterolemia in influencing the long-term response to therapy and the risk of atherosclerosis. Methods and Results A cohort of 370 patients with clinically diagnosed FH were screened for monogenic mutations and a low-density lipoprotein-rising genetic risk score >0.69 to identify polygenic cause. Medical records were reviewed to estimate the response to lipid-lowering therapies and the occurrence of major atherosclerotic cardiovascular events during a median follow-up of 31.0 months. A subgroup of patients (n=119) also underwent coronary computed tomographic angiography for the evaluation of coronary artery calcium score and severity of coronary stenosis as compared with 135 controls. Two hundred nine (56.5%) patients with hypercholesterolemia were classified as monogenic (FH/M+), 89 (24.1%) as polygenic, and 72 (19.5%) genetically undefined (FH/M-). The response to lipid-lowering therapy was poorest in monogenic, whereas it was comparable in patients with polygenic hypercholesterolemia and genetically undetermined. Mean coronary artery calcium score and the prevalence of coronary artery calcium >100 units were significantly higher in FH/M+ as compared with both FH/M- and controls. Finally, after adjustments for confounders, we observed a 5-fold higher risk of incident major atherosclerotic cardiovascular events in FH/M+ (hazard ratio, 4.8; 95% CI, 1.06-21.36; P <subscript>adj</subscript> =0.041). Conclusions Monogenic cause of FH is associated with lower response to conventional cholesterol-lowering therapies as well as with increased burden of coronary atherosclerosis and risk of atherosclerotic-related events. Genetic testing for hypercholesterolemia is helpful in providing important prognostic information.
- Subjects :
- Adult
Atherosclerosis blood
Atherosclerosis epidemiology
Biomarkers blood
Cardiovascular Diseases blood
Cardiovascular Diseases epidemiology
Coronary Artery Disease blood
Coronary Artery Disease epidemiology
Female
Follow-Up Studies
Humans
Hyperlipoproteinemia Type II complications
Hyperlipoproteinemia Type II drug therapy
Incidence
Italy epidemiology
Male
Middle Aged
Prognosis
Prospective Studies
Retrospective Studies
Risk Factors
Time Factors
Atherosclerosis complications
Cholesterol, LDL blood
Cholinergic Antagonists therapeutic use
Coronary Artery Disease complications
Hyperlipoproteinemia Type II genetics
Registries
Subjects
Details
- Language :
- English
- ISSN :
- 2047-9980
- Volume :
- 10
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Journal of the American Heart Association
- Publication Type :
- Academic Journal
- Accession number :
- 33890476
- Full Text :
- https://doi.org/10.1161/JAHA.120.018932